The UT MD Anderson Cancer Center Community Clinical Oncology Program Research Bas

描述（由申请人提供）：MD安德森癌症中心CCOP研究基地（RB）是MDACC内进行跨学科癌症控制研究的场所，并将该研究与社区肿瘤学家和其他学术中心联系起来，以改善患者护理。假设：我们的癌症中心RB，利用其临床医生，基础和人口科学研究人员，社区合作伙伴的全面广度和范围，以及临床研究各个方面的强大专业知识，同时利用MDACC的可用资源，可以通过团队科学和临床研究创新的过程，创造和传播癌症控制的关键新知识。具体目标：目标1。在癌症控制领域进行干预性临床试验和其他前瞻性研究，以改善受癌症影响或有癌症复发风险的患者的健康和福祉。(1a)开发和进行综合健康方面的临床试验和其他前瞻性研究，以优化癌症患者和家庭的健康，生活质量和临床结果;（1b）开发和进行干预性试验和前瞻性研究，旨在了解和减少癌症治疗毒性的负担;（1c）将新方法纳入临床试验的设计、实施和分析。目标2.在我们的社区肿瘤学站点，学术癌症中心的教职员工和研究员以及普通公众中推广癌症控制科学。(2a)加强临床前和临床研究人员之间的互动，以便更好地为临床试验的设计提供信息，并加强对试点数据和相关科学的收集和解释;（2b）开展与所有利益攸关方相关的癌症控制研究，并收集患者报告的结果数据和与观察到的患者行为相关的数据;（2c）利用多种交流方式宣传癌症控制研究所涉的健康目标和逐步进程;（2d）利用指导和机构领导，促进将青年调查员、女医生和女科学家纳入民间社会调查委员会的研究基地;（2e）制定和分享最佳做法，将代表性不足的人群纳入我们的临床研究和研究团队。 相关性（参见说明）：MD安德森癌症中心CCOP研究基地直接向社区环境中的患者提供创新研究，以改善患者护理并促进影响癌症医学领域的新信息的发现和传播。

DESCRIPTION (provided by applicant): The MD Anderson Cancer Center CCOP Research Base (RB) is a venue for transdisciplinary cancer control research within MDACC, and connecting this research to community oncologists and other academic centers, in order to improve patient care. Hypothesis: our cancer center RB, using its full breadth and scope of clinicians, basic and population science researchers, community partners, and robust expertise in all aspects of clinical investigation, while leveraging the resources available at MDACC, can create and disseminate critical new knowledge in cancer control through the process of team science and clinical research innovation. Specific aims: Aim 1. To conduct interventional clinical trials and other prospective studies in the realm of cancer control to enhance the health and well-being of patients affected by cancer or at risk for cancer recurrence. (1a) To develop and conduct clinical trials and other prospective studies in integrative health in order to optimize health, quality of life, and clinical outcomes of patients and families across the cancer continuum; (1b) To develop and conduct interventional trials and prospective studies directed at understanding and reducing the burden of cancer treatment toxicity; (1c) To incorporate novel approaches to the design, conduct, and analysis of clinical trials. Aim 2. To promote cancer control science among our community oncology sites, academic cancer center faculty and fellows, and the lay public. (2a) To enhance interactions between preclinical and clinical investigators to better inform the design of clinical trials and enhance the collection and interpretation of pilot data and correlative science; (2b) To develop cancer control studies relevant to all stakeholders and involving the collection of patient-reported outcome data and data related to observed patient behaviors; (2c) To use multiple modes of communication to disseminate the healthy goals and step-by-step processes involved in cancer control research; (2d) To use mentorship and institutional leadership to promote the inclusion of young investigators and women physicians and scientists in the CCOP research base; (2e) To develop and share best practices for the inclusion of underrepresented populations in our clinical research studies and on our research teams. RELEVANCE (See instructions): The MD Anderson Cancer Center CCOP Research Base delivers innovative studies directly to patients in the community setting, in order to improve patient care and facilitate the discovery and dissemination of new information that impacts the field of cancer medicine.